EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase

JingCheng Zhang, Sheng Zhou, SiSi Jiang, Fang He, Yan Tu, HuiXian Hu

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05939-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von JingCheng Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, China. Hauptthemen laut MEDLINE: Imatinib Mesylate, Cytidine Deaminase, Proto-Oncogene Proteins c-myc, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateCytidine DeaminaseProto-Oncogene Proteins c-mycXenograft Model Antitumor AssaysAnimalsHumansMiceCell Line, TumorLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFemaleAntineoplastic AgentsTranslocation, GeneticMaleCell ProliferationLymphomaGene Expression Regulation, NeoplasticAICDA (Activation-Induced Cytidine Deaminase)

Stichwörter der Autor:innen

Activation-induced cytidine deaminaseC-MycDiffuse large B-cell lymphomaDouble-hit lymphomaImatinib mesylate

Substanzen

Imatinib MesylateCytidine DeaminaseProto-Oncogene Proteins c-mycMYC protein, humanAICDA (Activation-Induced Cytidine Deaminase)Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, China.
  • Department of Hematology, Lanxi People's Hospital, Lanxi, 321100, China.
  • Department of Internal Medicine, Yongkang Traditional Chinese Medicine Hospital, Yongkang, 321000, China.
  • Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, China. huhuixian@zju.edu.cn.

Zitieren

APA

Zhang, J., Zhou, S., Jiang, S., He, F., Tu, Y., & Hu, H. (2024). Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05939-4

Vancouver

Zhang J, Zhou S, Jiang S, He F, Tu Y, Hu H. Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05939-4

BibTeX
@article{Zhang2024,
  author = {Zhang, JingCheng and Zhou, Sheng and Jiang, SiSi and He, Fang and Tu, Yan and Hu, HuiXian},
  title = {Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05939-4}
}
Kostenlos starten →